TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
URGN

UroGen Pharma Ltd

Healthcare · Biotechnology

40.60$ -0.2% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Balance Sheet

UroGen Pharma Ltd (URGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 253 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet URGN
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
194 178 201 282 302 286 248 209 185 200 254 253
182 169 197 279 295 276 237 197 169 186 237 235
119 96 132 220 125 172 104 93 90 111 111 79
147 138 165 241 250 237 196 157 127 120 142 108
13 15 14 17 23 20 20 20 20 33 55 89
5.0 5.7 7.2 7.4 7.6 9.2 7.6 7.1 8.3 16 21 25
236 244 241 252 276 295 294 302 300 306 378 385
26 31 26 34 33 46 42 48 42 46 51 62
0.9 0.8 0.8 1.6 0.8 3.1 1.4 1.5 1.6 – 1.9 2.1
4.0 6.5 6.3 8.3 5.6 11 15 14 10 12 17 40
99 99 98 98 122 122 122 123 122 122 190 189
-42 -65 -40 30 26 -8.8 -46 -93 -115 -105 -124 -132
-653 -679 -712 -745 -769 -806 -850 -900 -933 -960 -983 -998
32 36 33 37 43 47 47 48 48 49 50 50

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?